Author

M. Elmadani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

D. Bulanova· 1 shared J. Hynninen· 1 shared J. Oikkonen· 1 shared K. Wennerberg· 1 shared L. Gall-Mas· 1 shared S. Hautaniemi· 1 shared S. Timonen· 1 shared T. Aittokallio· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

D. Bulanova

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cells

D. Bulanova, Y. Akimov, W. Senkowski, J. Oikkonen, L. Gall-Mas, S. Timonen, M. Elmadani, J. Hynninen, S. Hautaniemi, T. Aittokallio, K. Wennerberg

This study identifies CK2 inhibition as a sensitizing strategy for RB1-deficient ovarian and breast cancer cells to replication-perturbing drugs, showing enhanced efficacy when combined with existing therapies.

bioRxiv · Nov 14, 2022 · PreprintCancer Biology